EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis

Bryanna Reinhardt iD, Patrick Lee, Joshua P Sasine

Cells · 2023

DOI: 10.3390/cells12040531 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Bryanna Reinhardt und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment option for patients suffering from B-cell- and plasma cell-derived hematologic malignancies and is being adapted for the treatment of solid cancers. However, CAR T is associated with frequently severe toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), macrophage activation syndrome (MAS), and prolonged cytopenias—a reduction in the number of mature blood cells of one or more lineage. Although we understand some drivers of these toxicities, their mechanisms remain under investigation. Since the CAR T regimen is a complex, multi-step process with frequent adverse events, ways to improve the benefit-to-risk ratio are needed. In this review, we discuss a variety of potential solutions being investigated to address the limitations of CAR T. First, we discuss the incidence and characteristics of CAR T-related cytopenias and their association with reduced CAR T-cell efficacy. We review approaches to managing or mitigating cytopenias during the CAR T regimen—including the use of growth factors, allogeneic rescue, autologous hematopoietic stem cell infusion, and alternative conditioning regimens. Finally, we introduce novel methods to improve CAR T-cell-infusion products and the implications of CAR T and clonal hematopoiesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHumansReceptors, Antigen, T-CellHematopoiesisCell- and Tissue-Based TherapyNeurotoxicity Syndromes

Stichwörter der Autor:innen

CAR Tbone marrow failureclonal hematopoiesisconditioningcytokine release syndromecytopeniahematopoietic stem cellsinflammatory toxicity

Substanzen

Receptors, Chimeric Antigencell-associated neurotoxicityReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
  • Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Department of Medicine, Division of Hematology and Cellular Therapy, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

ORCID-Profile: Bryanna Reinhardt

Förderung

  • NCI NIH HHS

Zitieren

APA

Reinhardt, B., Lee, P., & Sasine, J. P. (2023). Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis. Cells. https://doi.org/10.3390/cells12040531

Vancouver

Reinhardt B, Lee P, Sasine JP. Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis. Cells. 2023. doi:10.3390/cells12040531

BibTeX
@article{Reinhardt2023,
  author = {Reinhardt, Bryanna and Lee, Patrick and Sasine, Joshua P},
  title = {Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12040531}
}
Kostenlos starten →